These findings highlight the potential of berberine as a radiosensitizer in the treatment of human breast cancer, as it exerts its effects through G2/M phase cell cycle arrest and the downregulation of the homologous recombination repair protein RAD51, ultimately increasing the therapeutic efficacy of radiation therapy (130). This evidence concerns the gene RAD51 and breast cancer.